Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Full kinetic modeling analysis of [18F]fluorocholine Positron Emission Tomography (PET) at initial diagnosis of high-grade glioma.
Rubí S, Bibilioni P, Villar M, Brell M, Valiente M, Galmés M, Toscano M, Matheu G, Chinchilla JL, Molina J, Luis Valera J, Ríos Á, López M, Peña C. Rubí S, et al. Neuroimage Clin. 2024 May 6;42:103616. doi: 10.1016/j.nicl.2024.103616. Online ahead of print. Neuroimage Clin. 2024. PMID: 38763039 Free PMC article.
We assessed the correlation between the kinetic parameters and the conventional static PET metrics (SUV(max), SUV(mean) and tumor-to-background ratio TBR). We explored the association between the [(18)F]F-CHO-PET quantitative parameters and relevant molecular biomarkers in …
We assessed the correlation between the kinetic parameters and the conventional static PET metrics (SUV(max), SUV(mean) and tumor-to- …
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Ricart AD, Ashton EA, Cooney MM, Sarantopoulos J, Brell JM, Feldman MA, Ruby KE, Matsuda K, Munsey MS, Medina G, Zambito A, Tolcher AW, Remick SC. Ricart AD, et al. Cancer Chemother Pharmacol. 2011 Oct;68(4):959-70. doi: 10.1007/s00280-011-1565-4. Epub 2011 Feb 9. Cancer Chemother Pharmacol. 2011. PMID: 21305290 Clinical Trial.
Two dose-limiting toxicities occurred at 225 mg/m(2), a transient ischemic attack and grade 3 transaminitis, thus ending dose escalation. Pharmacokinetic data indicated dose-related increases in C (max) and AUC values, although substantial inter-subject variability was obs …
Two dose-limiting toxicities occurred at 225 mg/m(2), a transient ischemic attack and grade 3 transaminitis, thus ending dose escalation. Ph …